Avadel Pharmaceuticals (AVDL) Long-Term Deferred Tax: 2009-2016
Historic Long-Term Deferred Tax for Avadel Pharmaceuticals (AVDL) over the last 1 years, with Dec 2016 value amounting to $10.3 million.
- Avadel Pharmaceuticals' Long-Term Deferred Tax fell 10.70% to $10.3 million in Q4 2016 from the same period last year, while for Dec 2016 it was $10.3 million, marking a year-over-year decrease of 10.70%. This contributed to the annual value of $10.3 million for FY2016, which is 10.70% down from last year.
- Per Avadel Pharmaceuticals' latest filing, its Long-Term Deferred Tax stood at $10.3 million for Q4 2016, which was down 8.01% from $11.2 million recorded in Q3 2016.
- In the past 5 years, Avadel Pharmaceuticals' Long-Term Deferred Tax ranged from a high of $13.1 million in Q4 2014 and a low of -$14.1 million during Q4 2012.
- Moreover, its 3-year median value for Long-Term Deferred Tax was $11.5 million (2015), whereas its average is $11.6 million.
- Its Long-Term Deferred Tax has fluctuated over the past 5 years, first skyrocketed by 566.93% in 2014, then fell by 11.61% in 2015.
- Avadel Pharmaceuticals' Long-Term Deferred Tax (Quarterly) stood at -$14.1 million in 2012, then surged by 80.14% to -$2.8 million in 2013, then spiked by 566.93% to $13.1 million in 2014, then fell by 11.61% to $11.6 million in 2015, then dropped by 10.70% to $10.3 million in 2016.
- Its last three reported values are $10.3 million in Q4 2016, $11.2 million for Q3 2016, and $11.4 million during Q2 2016.